BCYC vs. PHAT, SPRY, TYRA, CDMO, CNTA, DYN, ALPN, RAPT, ELVN, and GNLX
Should you be buying Bicycle Therapeutics stock or one of its competitors? The main competitors of Bicycle Therapeutics include Phathom Pharmaceuticals (PHAT), ARS Pharmaceuticals (SPRY), Tyra Biosciences (TYRA), Avid Bioservices (CDMO), Centessa Pharmaceuticals (CNTA), Dyne Therapeutics (DYN), Alpine Immune Sciences (ALPN), RAPT Therapeutics (RAPT), Enliven Therapeutics (ELVN), and Genelux (GNLX). These companies are all part of the "pharmaceutical preparations" industry.
Bicycle Therapeutics (NASDAQ:BCYC) and Phathom Pharmaceuticals (NASDAQ:PHAT) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their profitability, analyst recommendations, community ranking, institutional ownership, risk, earnings, media sentiment, dividends and valuation.
In the previous week, Bicycle Therapeutics had 2 more articles in the media than Phathom Pharmaceuticals. MarketBeat recorded 6 mentions for Bicycle Therapeutics and 4 mentions for Phathom Pharmaceuticals. Bicycle Therapeutics' average media sentiment score of 0.41 beat Phathom Pharmaceuticals' score of 0.00 indicating that Bicycle Therapeutics is being referred to more favorably in the media.
Bicycle Therapeutics has a beta of 0.75, meaning that its stock price is 25% less volatile than the S&P 500. Comparatively, Phathom Pharmaceuticals has a beta of 0.45, meaning that its stock price is 55% less volatile than the S&P 500.
Phathom Pharmaceuticals has a net margin of 0.00% compared to Bicycle Therapeutics' net margin of -621.69%. Phathom Pharmaceuticals' return on equity of 0.00% beat Bicycle Therapeutics' return on equity.
Bicycle Therapeutics presently has a consensus price target of $48.75, suggesting a potential upside of 141.34%. Phathom Pharmaceuticals has a consensus price target of $23.33, suggesting a potential upside of 124.36%. Given Bicycle Therapeutics' higher probable upside, equities research analysts clearly believe Bicycle Therapeutics is more favorable than Phathom Pharmaceuticals.
86.2% of Bicycle Therapeutics shares are held by institutional investors. Comparatively, 93.1% of Phathom Pharmaceuticals shares are held by institutional investors. 10.2% of Bicycle Therapeutics shares are held by company insiders. Comparatively, 7.5% of Phathom Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Bicycle Therapeutics has higher revenue and earnings than Phathom Pharmaceuticals. Bicycle Therapeutics is trading at a lower price-to-earnings ratio than Phathom Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Bicycle Therapeutics received 60 more outperform votes than Phathom Pharmaceuticals when rated by MarketBeat users. Likewise, 67.47% of users gave Bicycle Therapeutics an outperform vote while only 61.90% of users gave Phathom Pharmaceuticals an outperform vote.
Summary
Bicycle Therapeutics beats Phathom Pharmaceuticals on 10 of the 17 factors compared between the two stocks.
Get Bicycle Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BCYC and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Bicycle Therapeutics Competitors List
Related Companies and Tools
